BACKGROUND: Dipeptidyl peptidase 4 (DPP-4; also known as CD26), a transmembrane receptor expressed on T cells, has a costimulatory function in activating T cells. In a mouse model, down-regulation of CD26 prevented graft-versus-host disease (GVHD) but preserved graft-versus-tumor effects. Whether inhibition of DPP-4 with sitagliptin may prevent acute GVHD after allogeneic stem-cell transplantation is not known. METHODS: We conducted a two-stage, phase 2 clinical trial to test whether sitagliptin plus tacrolimus and sirolimus would reduce the incidence of grade II to IV acute GVHD from 30% to no more than 15% by day 100. Patients received myeloablative conditioning followed by mobilized peripheral-blood stem-cell transplants. Sitagliptin was given orally at a dose of 600 mg every 12 hours starting the day before transplantation until day 14 after transplantation. RESULTS: A total of 36 patients who could be evaluated, with a median age of 46 years (range, 20 to 59), received transplants from matched related or unrelated donors. Acute GVHD occurred in 2 of 36 patients by day 100; the incidence of grade II to IV GVHD was 5% (95% confidence interval [CI], 1 to 16), and the incidence of grade III or IV GVHD was 3% (95% CI, 0 to 12). Nonrelapse mortality was zero at 1 year. The 1-year cumulative incidences of relapse and chronic GVHD were 26% (95% CI, 13 to 41) and 37% (95% CI, 22 to 53), respectively. GVHD-free, relapse-free survival was 46% (95% CI, 29 to 62) at 1 year. Toxic effects were similar to those seen in patients undergoing allogeneic stem-cell transplantation. CONCLUSIONS: In this nonrandomized trial, sitagliptin in combination with tacrolimus and sirolimus resulted in a low incidence of grade II to IV acute GVHD by day 100 after myeloablative allogeneic hematopoietic stem-cell transplantation. (Funded by the National Heart, Lung, and Blood Institute; ClinicalTrials.gov number, NCT02683525.).
BACKGROUND:Dipeptidyl peptidase 4 (DPP-4; also known as CD26), a transmembrane receptor expressed on T cells, has a costimulatory function in activating T cells. In a mouse model, down-regulation of CD26 prevented graft-versus-host disease (GVHD) but preserved graft-versus-tumor effects. Whether inhibition of DPP-4 with sitagliptin may prevent acute GVHD after allogeneic stem-cell transplantation is not known. METHODS: We conducted a two-stage, phase 2 clinical trial to test whether sitagliptin plus tacrolimus and sirolimus would reduce the incidence of grade II to IV acute GVHD from 30% to no more than 15% by day 100. Patients received myeloablative conditioning followed by mobilized peripheral-blood stem-cell transplants. Sitagliptin was given orally at a dose of 600 mg every 12 hours starting the day before transplantation until day 14 after transplantation. RESULTS: A total of 36 patients who could be evaluated, with a median age of 46 years (range, 20 to 59), received transplants from matched related or unrelated donors. Acute GVHD occurred in 2 of 36 patients by day 100; the incidence of grade II to IV GVHD was 5% (95% confidence interval [CI], 1 to 16), and the incidence of grade III or IV GVHD was 3% (95% CI, 0 to 12). Nonrelapse mortality was zero at 1 year. The 1-year cumulative incidences of relapse and chronic GVHD were 26% (95% CI, 13 to 41) and 37% (95% CI, 22 to 53), respectively. GVHD-free, relapse-free survival was 46% (95% CI, 29 to 62) at 1 year. Toxic effects were similar to those seen in patients undergoing allogeneic stem-cell transplantation. CONCLUSIONS: In this nonrandomized trial, sitagliptin in combination with tacrolimus and sirolimus resulted in a low incidence of grade II to IV acute GVHD by day 100 after myeloablative allogeneic hematopoietic stem-cell transplantation. (Funded by the National Heart, Lung, and Blood Institute; ClinicalTrials.gov number, NCT02683525.).
Authors: J L Gajewski; L D Petz; L Calhoun; S O'Rourke; E M Landaw; N R Lyddane; L A Hunt; G J Schiller; W G Ho; R E Champlin Journal: Blood Date: 1992-06-01 Impact factor: 22.113
Authors: Jeanette E Boudreau; Fabio Giglio; Ted A Gooley; Philip A Stevenson; Jean-Benoît Le Luduec; Brian C Shaffer; Raja Rajalingam; Lihua Hou; Carolyn Katovich Hurley; Harriet Noreen; Elaine F Reed; Neng Yu; Cynthia Vierra-Green; Michael Haagenson; Mari Malkki; Effie W Petersdorf; Stephen Spellman; Katharine C Hsu Journal: J Clin Oncol Date: 2017-05-18 Impact factor: 44.544
Authors: Shernan G Holtan; Todd E DeFor; Aleksandr Lazaryan; Nelli Bejanyan; Mukta Arora; Claudio G Brunstein; Bruce R Blazar; Margaret L MacMillan; Daniel J Weisdorf Journal: Blood Date: 2015-01-15 Impact factor: 22.113
Authors: Roberto Rodriguez; Ryotaro Nakamura; Joycelynne M Palmer; Pablo Parker; Sepideh Shayani; Auyaporn Nademanee; David Snyder; Vinod Pullarkat; Neil Kogut; Joseph Rosenthal; Eileen Smith; Chatchada Karanes; Margaret O'Donnell; Amrita Y Krishnan; David Senitzer; Stephen J Forman Journal: Blood Date: 2009-11-19 Impact factor: 22.113
Authors: D Przepiorka; D Weisdorf; P Martin; H G Klingemann; P Beatty; J Hows; E D Thomas Journal: Bone Marrow Transplant Date: 1995-06 Impact factor: 5.483
Authors: Mehdi Hamadani; Laura F Gibson; Scot C Remick; Sijin Wen; William Petros; William Tse; Kathleen M Brundage; Jeffrey A Vos; Aaron Cumpston; Pamela Bunner; Michael D Craig Journal: J Clin Oncol Date: 2013-10-28 Impact factor: 44.544
Authors: Wael Saber; Corey S Cutler; Ryotaro Nakamura; Mei-Jie Zhang; Ehab Atallah; J Douglas Rizzo; Richard T Maziarz; Jorge Cortes; Matt E Kalaycio; Mary M Horowitz Journal: Blood Date: 2013-07-11 Impact factor: 22.113
Authors: Yi-Bin Chen; Nirav N Shah; Anne S Renteria; Corey Cutler; Johan Jansson; Mona Akbari; Chunlin Chen; Syed Quadri; Andrejus Parfionovas; Steven M Devine Journal: Blood Adv Date: 2019-12-10
Authors: Marie Bleakley; Alison Sehgal; Stuart Seropian; Melinda A Biernacki; Elizabeth F Krakow; Ann Dahlberg; Heather Persinger; Barbara Hilzinger; Paul J Martin; Paul A Carpenter; Mary E Flowers; Jenna Voutsinas; Theodore A Gooley; Keith Loeb; Brent L Wood; Shelly Heimfeld; Stanley R Riddell; Warren D Shlomchik Journal: J Clin Oncol Date: 2022-01-10 Impact factor: 50.717
Authors: Hal E Broxmeyer; Karmen K Yoder; Yu-Chien Wu; Gary D Hutchins; Scott H Cooper; Sherif S Farag Journal: Stem Cell Rev Rep Date: 2021-07-13 Impact factor: 6.692
Authors: Charles E Leonard; James H Flory; Robert Likić; Olayinka O Ogunleye; Li Wei; Ian Wong Journal: Br J Clin Pharmacol Date: 2021-05-04 Impact factor: 3.716
Authors: Khaled R Alkharsah; Salma Ali Aljaroodi; Jawad Ur Rahman; Awatif N Alnafie; Reem Al Dossary; Reem Y Aljindan; Amani M Alnimr; Jamal Hussen Journal: PLoS One Date: 2022-04-12 Impact factor: 3.240